{'fraction_non_alphanumeric': 0.01839926402943882, 'fraction_numerical': 0.00827966881324747, 'mean_word_length': 5.437869822485207, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ginkgetin Inhibits Growth and Invasion of Endometrial Carcinoma by Disruption of Janus Kinase 1/Signal Transducers and Activators of Transcription 3 and Phosphoinositide-3-Kinase/ Protein Kinase B Pathways

Ginkgetin, a bioflavonoid derived from Ginkgo biloba leaves has been shown to promote tumor cell apoptosis and suppress cell growth in a variety of tumors. This study has examined the role and mechanism of ginkgetin on the tumorigenesis of endometrial carcinoma. Results of the studies show that ginkgetin treatment led to a dose-dependent decrease in cell viability, enhanced expression of cleaved caspase-3 protein, and reduced expression of Bcl-2 protein. In addition, cell migration and invasion of HEC1B and Ishikawa cells were repressed by ginkgetin treatment. Levels of phosphoprotein kinase B, Janus kinase 1, and signal transducers and activators of transcription 3 were decreased in HEC1B and Ishikawa cells by ginkgetin treatment. In conclusion, ginkgetin presents with potential for further investigations into its possible role in management of endometrial carcinoma.